Speculation is mounting that Johnson & Johnson could buy its Danish R&D partner Genmab, a pairing that has created the successful blood cancer drug Darzalex. J&J this year bought Swiss biotech ...

Analysts' ratings for Genmab GMAB over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

Management revised its revenue guidance upwards while lowering its expense forecast. Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising ...

12 analysts have expressed a variety of opinions on Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Genmab (GMAB) has released an update. Genmab’s revenue surged by 29% in the first nine months of 2024, reaching DKK 15,085 million, primarily driven by increased royalties from its ...

Genmab (NASDAQ:GMAB) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Genmab to report an ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at $50.00. Ram Selvaraju’s rating is based on Genmab’s ...